Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

Muscular dystrophy is caused by defects in certain genes, with type determined by the abnormal gene. In 1986, researchers discovered the gene that, when defective or flawed, causes Duchenne ...

Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...

Limb-girdle muscular dystrophy type 2D (LGMD2D/R3) is a rare genetic disorder caused by mutations in the SGCA gene, leading to defective folding and the loss of functional α-sarcoglycan, with ...

candidate for myotonic dystrophy type 1 (DM1), and del-brax for facioscapulohumeral muscular dystrophy (FSHD). All three candidates are based on the same TfR1-targeting antibody component.

The company's portfolio of FDA-approved brands includes: In addition to this Duchenne muscular dystrophy program, the company also has Phase 2 clinical studies underway evaluating its ifetroban ...

a Phase 1/2 clinical study of ENTR-601-44 targeting Duchenne muscular dystrophy (DMD). This study will evaluate the safety, tolerability, and effectiveness of ENTR-601-44 in patients with specific ...

The rate of progression of the muscular dystrophies depends on the type of dystrophy. While some progress slowly, others confine the patient to a wheelchair within a few years. Significant advances in ...

Duchenne muscular dystrophy (DMD) is the most common type. It’s caused by flaws in the ... Children who take this medicine are able to walk for 2 to 5 years longer than they would without ...